Literature DB >> 18989900

Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.

Brenda M Birmann1, Elizabeth C Breen, Sherri Stuver, Beverly Cranston, Otoniel Martínez-Maza, Kerstin I Falk, Akihiko Okayama, Barrie Hanchard, Nancy Mueller, Michie Hisada.   

Abstract

The natural history of human T-lymphotropic virus type I (HTLV-I) has been shown to differ markedly by geographic area. The differences include contrasting patterns of risk of adult T-cell lymphoma (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), which may be due in part to differences in host immune response to infection. To characterize variations in host immunity across populations, we compared serologic immune marker patterns in HTLV-I-endemic populations in Japan and Jamaica. We matched 204 participants with archived blood from the Miyazaki Cohort Study (Japan) and the Food Handlers Study (Jamaica)-i.e., 51 HTLV-I-positive ("carriers") and 51 HTLV-I-negative individuals ("noncarriers") from each population-by age, sex and blood collection year. We compared plasma concentrations of markers of T-cell-mediated (antigen-specific) and nonspecific immunity using regression models and correlation coefficients. Compared to Jamaican HTLV-I noncarriers, Japanese noncarriers had higher covariate-adjusted mean levels of T-cell activation markers, including antibody to Epstein-Barr virus nuclear antigen-1 (reciprocal titer 27 vs. 71, respectively, p=0.005), soluble interleukin-2 receptor-alpha (477 vs. 623 pg/mL, p=0.0008) and soluble CD30 (34 vs. 46 U/mL, p=0.0001) and lower levels of C-reactive protein (1.1 vs. 0.43 microg/mL, p=0.0004). HTLV-I infection was associated with activated T-cell immunity in Jamaicans but with diminished T-cell immunity in Japanese persons. The observed population differences in background and HTLV-I-related host immunity correspond closely to the divergent natural histories of infection observed among HTLV-I carriers in Japan and Jamaica and corroborate a role for host immune status in the contrasting patterns of ATL and HAM/TSP risk. Copyright (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18989900      PMCID: PMC2701897          DOI: 10.1002/ijc.24012

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  41 in total

1.  Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.

Authors:  J M Fernandez-Real; M Vayreda; C Richart; C Gutierrez; M Broch; J Vendrell; W Ricart
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

2.  A nested case-control study of risk factors for adult T-cell leukemia/lymphoma among human T-cell lymphotropic virus type-I carriers in Japan.

Authors:  Kokichi Arisaw; Shigeru Katamine; Shimeru Kamihira; Kenji Kurokawa; Takashi Sawada; Midori Soda; Hiroshi Doi; Hiroshi Saito; Satoshi Shirahama
Journal:  Cancer Causes Control       Date:  2002-09       Impact factor: 2.506

Review 3.  Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration.

Authors:  Kate Barmak; Edward Harhaj; Christian Grant; Timothy Alefantis; Brian Wigdahl
Journal:  Virology       Date:  2003-03-30       Impact factor: 3.616

4.  Increased HTLV type 1 tax specific CD8+ cells in HTLV type 1-asociated myelopathy/tropical spastic paraparesis: correlation with HTLV type 1 proviral load.

Authors:  R Kubota; M Nagai; T Kawanishi; M Osame; S Jacobson
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-01       Impact factor: 2.205

5.  Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load.

Authors:  M Nagai; R Kubota; T F Greten; J P Schneck; T P Leist; S Jacobson
Journal:  J Infect Dis       Date:  2000-12-15       Impact factor: 5.226

6.  C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.

Authors:  Paul M Ridker; Julie E Buring; Nancy R Cook; Nader Rifai
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

7.  SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.

Authors:  Noémi Nagy; Akihiko Maeda; Kentaro Bandobashi; Loránd L Kis; Jun Nishikawa; Pankaj Trivedi; Alberto Faggioni; George Klein; Eva Klein
Journal:  Int J Cancer       Date:  2002-08-01       Impact factor: 7.396

8.  Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers.

Authors:  Masaki Akimoto; Tomohiro Kozako; Takashi Sawada; Kakushi Matsushita; Atsuo Ozaki; Heiichiro Hamada; Hideaki Kawada; Makoto Yoshimitsu; Masahito Tokunaga; Koichi Haraguchi; Kimiharu Uozumi; Naomichi Arima; Chuwa Tei
Journal:  J Med Virol       Date:  2007-07       Impact factor: 2.327

9.  Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Authors:  C L Tendler; S J Greenberg; W A Blattner; A Manns; E Murphy; T Fleisher; B Hanchard; O Morgan; J D Burton; D L Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

Review 10.  Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo.

Authors:  F Mortreux; A-S Gabet; E Wattel
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

View more
  9 in total

1.  Soluble IL-2 receptor and beta-2 microglobulin as possible serologic markers of neurologic disease in HTLV-1 infection.

Authors:  Cristina Toledo-Cornell; Silvane Santos; Gloria Orge; Marshall J Glesby; Edgar M Carvalho
Journal:  J Med Virol       Date:  2013-09-11       Impact factor: 2.327

Review 2.  The contribution of Asian researchers to the field of rheumatology.

Authors:  Yoshihisa Yamano; Kusuki Nishioka
Journal:  Nat Rev Rheumatol       Date:  2010-02       Impact factor: 20.543

3.  Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30.

Authors:  Colleen Pelser; Jaap Middeldorp; Sam M Mbulaiteye; Carmela Lauria; Angelo Messina; Enza Viviano; Nino Romano; Francesco Vitale; James J Goedert
Journal:  Infect Agent Cancer       Date:  2010-10-12       Impact factor: 2.965

Review 4.  Human T-lymphotropic virus type 1 (HTLV-1) and regulatory T cells in HTLV-1-associated neuroinflammatory disease.

Authors:  Natsumi Araya; Tomoo Sato; Naoko Yagishita; Hitoshi Ando; Atae Utsunomiya; Steven Jacobson; Yoshihisa Yamano
Journal:  Viruses       Date:  2011-08-25       Impact factor: 5.048

5.  Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus.

Authors:  Shimeru Kamihira; Tetsuya Usui; Tatsuki Ichikawa; Naoki Uno; Yoshitomo Morinaga; Sayaka Mori; Kazuhiro Nagai; Daisuke Sasaki; Hiroo Hasegawa; Katsunori Yanagihara; Takuya Honda; Yasuaki Yamada; Masako Iwanaga; Takashi Kanematu; Kazuhiko Nakao
Journal:  Virol J       Date:  2012-02-15       Impact factor: 4.099

6.  Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature.

Authors:  Joanne R Winter; Charlotte Jackson; Joanna Ea Lewis; Graham S Taylor; Olivia G Thomas; Helen R Stagg
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

7.  In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Mineki Saito; Toshio Matsuzaki; Yorifumi Satou; Jun-Ichirou Yasunaga; Kousuke Saito; Kimiyoshi Arimura; Masao Matsuoka; Yoshiro Ohara
Journal:  Retrovirology       Date:  2009-02-19       Impact factor: 4.602

8.  Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.

Authors:  Mara M Epstein; Bernard Rosner; Elizabeth C Breen; Julie L Batista; Edward L Giovannucci; Larry Magpantay; Jon C Aster; Scott J Rodig; Kimberly A Bertrand; Francine Laden; Otoniel Martínez-Maza; Brenda M Birmann
Journal:  Haematologica       Date:  2018-06-21       Impact factor: 9.941

9.  Cardiovascular risk profile in patients with myelopathy associated with HTLV-1.

Authors:  Fabio Luís Silva do Prado; Renata Prado; Ana Marice Teixeira Ladeia
Journal:  Braz J Infect Dis       Date:  2017-03-07       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.